Serum hyaluronan in patients with multiple myeloma: Correlation with survival and Ig concentration
Serum hyaluronan in patients with multiple myeloma: Correlation with survival and Ig concentration
复制标题
DOI：
10.1182/blood.v93.12.4144.412a36_4144_4148
复制
发表时间：
1999-06-15
期刊：
影响因子：
20.3
通讯作者：
Lilja, K
中科院分区：
文献类型：
--
作者：
Dahl, IMS;Turesson, I;Lilja, K
分析了386例骨髓瘤患者诊断时的血清透明质酸（HYA）。中位年龄为68岁（范围：32 - 87岁）。IG类的分布是典型的（58% IgG，21%伊加，1% IgD和20%轻链疾病）。患者包括58%的III期、33%的II期和9%的I期，大多数（82%）的HYA值在中间范围内（10 ~ 120 μ g/L），13%具有高值（>120 μ g/L），5%具有异常低值（0至9 μ g/L）。首次报道了具有异常低的HYA血清值的患者组。生存率与血清HYA水平呈负相关（P = 0.015），当分别进行测试时，HYA值异常低或异常高的患者的中位生存期显著较短（分别为21.1和19.7个月）比那些具有中等HYA浓度（32.6个月; P = .005），根据分期和生化标志物判断，HYA水平异常低或高的患者病情更严重。有趣的是，血清中的HYA值和M组分浓度之间呈负相关。百分之五十的HYA值异常低的患者患有伊加骨髓瘤。总之，血清HYA浓度可能对选定的多发性骨髓瘤病例具有预后价值。进一步的研究将进行阐明可能的解释，我们的发现，特别是那些相关的HYA细胞表面结合蛋白，（C）1999年由美国血液学会。
Serum from 386 myeloma patients were analyzed for serum hyaluronan (HYA) at diagnosis. Median age was 68 years (range, 32 to 87 years). The distribution of Ig classes was typical (58% IgG, 21% IgA, 1% IgD, and 20% light chain disease). The patients comprised 58% in stage III, 33% in stage II, and 9% in stage I, The majority (82%) had HYA values within an intermediate range (10 to 120 mu g/L), 13% had high values (>120 mu g/L), and 5% had abnormally low values (0 to 9 mu g/L), For the first time, a patient group with abnormally low HYA serum values is reported. An inverse correlation between survival and HYA serum level was found (P = .015), When tested separately, patients with abnormally low or high HYA values had significantly shorter median survival (21.1 and 19.7 months, respectively) than those with an intermediate HYA concentration (32.6 months; P = .005), Patients with abnormally low or high HYA levels had more advanced disease as judged by staging and biochemical markers. Interestingly, there was an inverse correlation between the HYA value and the M-component concentration in serum. Fifty percent of patients with abnormally low HYA values had IgA myelomas. In conclusion, the serum concentration of HYA may be of prognostic value in selected cases of multiple myeloma. Further studies will be performed to elucidate possible explanations for our findings, especially those related to the HYA cell surface binding proteins, (C) 1999 by The American Society of Hematology.